Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal

Mauro Viganò, Alessandra Brocchieri, Angiola Spinetti, Serena Zaltron, Giampaolo Mangia, Floriana Facchetti, Alessandro Fugazza, Francesco Castelli, Massimo Colombo, Pietro Lampertico

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

•Tenofovir (TDF) is increasingly used to treat CHB patients worldwide.•We describe two cases of TDF-induced Fanconi syndrome in CHB patients.•Fanconi syndrome reverted after TDF withdrawal while HBV was suppressed by ETV.•Glomerular and tubular function should be carefully monitored in patients under TDF.•Several factors, including age and ADV exposure, may increase the risk of this complication. Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor widely used to treat patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Despite the excellent safety records of this regimen, a few cases of acute renal failure and Fanconi syndrome have been reported among HIV patients exposed to TDF. In the HBV monoinfection scenario, only two cases of TDF-associated Fanconi syndrome have been reported thus far. Here, we describe two additional patients with chronic hepatitis B (CHB) who developed a TDF-induced Fanconi syndrome that reverted after TDF withdrawal and had viral replication fully suppressed upon switching to entecavir (ETV). Though the overall risk of TDF associated severe renal toxicity in HBV patients appears to be negligible, both glomerular and tubular function should be monitored in patients exposed to TDF, especially when other renal risk factors or a history of previous exposure to adefovir dipivoxil (ADV) are present.

Original languageEnglish
Pages (from-to)600-603
Number of pages4
JournalJournal of Clinical Virology
Volume61
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Tenofovir
Fanconi Syndrome
Chronic Hepatitis B
Hepatitis B virus
HIV

Keywords

  • Adverse drug reaction
  • Entecavir
  • Fanconi syndrome
  • Hepatitis B virus
  • Tenofovir

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. / Viganò, Mauro; Brocchieri, Alessandra; Spinetti, Angiola; Zaltron, Serena; Mangia, Giampaolo; Facchetti, Floriana; Fugazza, Alessandro; Castelli, Francesco; Colombo, Massimo; Lampertico, Pietro.

In: Journal of Clinical Virology, Vol. 61, No. 4, 2014, p. 600-603.

Research output: Contribution to journalArticle

Viganò, Mauro ; Brocchieri, Alessandra ; Spinetti, Angiola ; Zaltron, Serena ; Mangia, Giampaolo ; Facchetti, Floriana ; Fugazza, Alessandro ; Castelli, Francesco ; Colombo, Massimo ; Lampertico, Pietro. / Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. In: Journal of Clinical Virology. 2014 ; Vol. 61, No. 4. pp. 600-603.
@article{f160aaad4b6641b5891b8918ab213a1a,
title = "Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal",
abstract = "•Tenofovir (TDF) is increasingly used to treat CHB patients worldwide.•We describe two cases of TDF-induced Fanconi syndrome in CHB patients.•Fanconi syndrome reverted after TDF withdrawal while HBV was suppressed by ETV.•Glomerular and tubular function should be carefully monitored in patients under TDF.•Several factors, including age and ADV exposure, may increase the risk of this complication. Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor widely used to treat patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Despite the excellent safety records of this regimen, a few cases of acute renal failure and Fanconi syndrome have been reported among HIV patients exposed to TDF. In the HBV monoinfection scenario, only two cases of TDF-associated Fanconi syndrome have been reported thus far. Here, we describe two additional patients with chronic hepatitis B (CHB) who developed a TDF-induced Fanconi syndrome that reverted after TDF withdrawal and had viral replication fully suppressed upon switching to entecavir (ETV). Though the overall risk of TDF associated severe renal toxicity in HBV patients appears to be negligible, both glomerular and tubular function should be monitored in patients exposed to TDF, especially when other renal risk factors or a history of previous exposure to adefovir dipivoxil (ADV) are present.",
keywords = "Adverse drug reaction, Entecavir, Fanconi syndrome, Hepatitis B virus, Tenofovir",
author = "Mauro Vigan{\`o} and Alessandra Brocchieri and Angiola Spinetti and Serena Zaltron and Giampaolo Mangia and Floriana Facchetti and Alessandro Fugazza and Francesco Castelli and Massimo Colombo and Pietro Lampertico",
year = "2014",
doi = "10.1016/j.jcv.2014.09.016",
language = "English",
volume = "61",
pages = "600--603",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal

AU - Viganò, Mauro

AU - Brocchieri, Alessandra

AU - Spinetti, Angiola

AU - Zaltron, Serena

AU - Mangia, Giampaolo

AU - Facchetti, Floriana

AU - Fugazza, Alessandro

AU - Castelli, Francesco

AU - Colombo, Massimo

AU - Lampertico, Pietro

PY - 2014

Y1 - 2014

N2 - •Tenofovir (TDF) is increasingly used to treat CHB patients worldwide.•We describe two cases of TDF-induced Fanconi syndrome in CHB patients.•Fanconi syndrome reverted after TDF withdrawal while HBV was suppressed by ETV.•Glomerular and tubular function should be carefully monitored in patients under TDF.•Several factors, including age and ADV exposure, may increase the risk of this complication. Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor widely used to treat patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Despite the excellent safety records of this regimen, a few cases of acute renal failure and Fanconi syndrome have been reported among HIV patients exposed to TDF. In the HBV monoinfection scenario, only two cases of TDF-associated Fanconi syndrome have been reported thus far. Here, we describe two additional patients with chronic hepatitis B (CHB) who developed a TDF-induced Fanconi syndrome that reverted after TDF withdrawal and had viral replication fully suppressed upon switching to entecavir (ETV). Though the overall risk of TDF associated severe renal toxicity in HBV patients appears to be negligible, both glomerular and tubular function should be monitored in patients exposed to TDF, especially when other renal risk factors or a history of previous exposure to adefovir dipivoxil (ADV) are present.

AB - •Tenofovir (TDF) is increasingly used to treat CHB patients worldwide.•We describe two cases of TDF-induced Fanconi syndrome in CHB patients.•Fanconi syndrome reverted after TDF withdrawal while HBV was suppressed by ETV.•Glomerular and tubular function should be carefully monitored in patients under TDF.•Several factors, including age and ADV exposure, may increase the risk of this complication. Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor widely used to treat patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Despite the excellent safety records of this regimen, a few cases of acute renal failure and Fanconi syndrome have been reported among HIV patients exposed to TDF. In the HBV monoinfection scenario, only two cases of TDF-associated Fanconi syndrome have been reported thus far. Here, we describe two additional patients with chronic hepatitis B (CHB) who developed a TDF-induced Fanconi syndrome that reverted after TDF withdrawal and had viral replication fully suppressed upon switching to entecavir (ETV). Though the overall risk of TDF associated severe renal toxicity in HBV patients appears to be negligible, both glomerular and tubular function should be monitored in patients exposed to TDF, especially when other renal risk factors or a history of previous exposure to adefovir dipivoxil (ADV) are present.

KW - Adverse drug reaction

KW - Entecavir

KW - Fanconi syndrome

KW - Hepatitis B virus

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=84922729207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922729207&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2014.09.016

DO - 10.1016/j.jcv.2014.09.016

M3 - Article

C2 - 25453573

AN - SCOPUS:84922729207

VL - 61

SP - 600

EP - 603

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 4

ER -